"GIP's Role in Obesity Research: A Controversial Debate"
TL;DR
A landmark study over a decade ago suggested a new approach to treating obesity and diabetes by activating gut hormone receptors GLP-1 and GIP. This approach was used by Eli Lilly to develop tirzepatide, a medicine for diabetes and weight loss. However, recent research has raised questions about the effectiveness of GIP in treating obesity, leading to conflicting views within the scientific community.
With GIP, obesity research is at odds Endpoints News
Want the full story? Read the original reporting
Read on Endpoints News